A terminally ill policyholder facing mounting medical bills and lost income can often tap cash from the same life-insurance policy that was supposed to pay out after death. The mechanism, known as an accelerated death benefit, is written into many existing contracts as a provision, rider, or endorsement. Federal tax rules allow qualifying payments to be excluded from income, and regulators in at least six states actively direct consumers to check for the feature before turning to outside buyers. Yet the gap between what policies already offer and what policyholders actually use persists, driven partly by uneven disclosure rules and partly by a secondary market that aggressively courts the terminally ill.
How accelerated death benefits work and why regulators are pushing them
The core idea is straightforward: a life-insurance company advances a portion of the death benefit to the policyholder while that person is still alive, triggered by a qualifying event such as a terminal diagnosis. Guidance in IRS Publication 554 confirms that certain amounts paid as accelerated death benefits before the insured’s death can be excluded from income if the insured is terminally or chronically ill. That tax treatment makes the payout more valuable dollar for dollar than selling a policy to a third party, where proceeds may be taxable and the sale price is typically less than the full death benefit.
State regulators have spelled out the option in consumer-facing guides. The California insurance guide defines an accelerated benefit provision as one allowing the owner to receive a portion of the death benefit early if the insured is diagnosed with a terminal illness or permanently confined to a nursing home. Texas consumer materials similarly state that an accelerated death benefit option can prepay some or all of the death benefit while the insured is still living. California statutory law goes further, with insurance code language defining the benefit as a provision, endorsement, or rider providing advance payment of death proceeds upon a qualifying event.
Other states emphasize not just definitions but process. Massachusetts regulation 211 CMR 55.00 details specific disclosure requirements insurers must meet both at the time of purchase and when a claim is triggered, including written explanations of how much of the face amount can be accelerated and what happens to any remaining benefit. New York’s Department of Financial Services has published a product outline describing terminal-illness life expectancy criteria that insurers must follow, such as requiring a physician’s certification that the insured is expected to die within a specified number of months. And Maine’s Bureau of Insurance explicitly tells consumers to check whether their policy has an accelerated death benefit provision before considering alternatives like viatical settlements or policy loans.
In practice, an accelerated death benefit can be structured in several ways. Some policies allow the owner to elect a fixed lump sum, while others offer periodic payments that resemble an income stream. Insurers typically cap the advance at a percentage of the face amount, often reducing it by administrative charges or an interest discount that reflects the early payment. Whatever remains of the death benefit is still payable to beneficiaries after the insured dies, adjusted for the amount already advanced. Because these payments are coming from the original insurer under a life policy, they are generally simpler for consumers to understand than a sale to an outside investor.
The viatical settlement gap and what disclosure rules have not fixed
The alternative to an accelerated death benefit is a viatical or life settlement, in which the policyholder sells the entire policy to a third-party investor for a lump sum below the face value. The Illinois Department of Insurance describes viatical settlements as selling the policy for less than the full death benefit, with the buyer taking over premium payments and collecting the full amount when the insured dies. The U.S. Securities and Exchange Commission has published an investor bulletin warning about the risks and regulatory complexity of life settlements, including the potential for fraud, illiquidity, and uncertainty about returns tied to an individual’s life expectancy. Both federal and state regulators position accelerated death benefits as the first option a terminally ill policyholder should consider, yet many consumers still end up in the secondary market.
One plausible explanation is uneven state-level disclosure. Massachusetts requires insurers to provide additional written disclosures at the time a claim is filed, not just at the point of sale. States without similar rules leave policyholders to discover the benefit on their own, often after a settlement broker has already made contact. In those jurisdictions, marketing from viatical and life-settlement firms can fill the information vacuum, emphasizing quick cash and downplaying the possibility that the policy already contains a built-in, tax-favored way to access funds.
The hypothesis that states with stronger post-2015 disclosure rules see lower viatical settlement uptake is logical but cannot be confirmed without comprehensive, comparable transaction data. Public reporting on settlement volumes is sparse, and differences in demographics, insurance ownership rates, and health-care costs could also influence how often policyholders sell their coverage. What is clear from existing regulatory materials is a consistent message: before signing away a policy, consumers should ask their insurer or agent whether an accelerated death benefit is available, how it would be taxed, and what it would mean for beneficiaries. As more states revisit disclosure standards, the gap between what policies already offer and what policyholders actually use may narrow, but for now it remains a critical fault line in end-of-life financial planning.
